RxDoctor Payments Data

Gina Joseph, MD

Internal Medicine · Royal Palm Beach, FLNPI 1346433737

Payments from drug & device makers

$1,239in general payments, 2019–2025

Across 57 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$225
  • Boehringer Ingelheim$209
  • Novo Nordisk$156
  • Abbott$131
  • Lilly USA, LLC$121
  • GSK$95
  • plus $302 from 7 others

What the payments were for

  • Food & beverage$1,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,239 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$37,802
Medicare patients
108
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin189$174,760
OzempicSemaglutide42$48,675
EliquisApixaban41$45,092
XareltoRivaroxaban23$27,042
JanuviaSitagliptin Phosphate32$23,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,280
MounjaroTirzepatide20$20,536
WegovySemaglutide12$15,488
FarxigaDapagliflozin Propanediol12$14,403
LinzessLinaclotide11$10,926
Tresiba Flextouch U-100Insulin Degludec12$6,839
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,214
Atorvastatin Calcium461$2,917
Albuterol Sulfate HfaAlbuterol Sulfate72$2,828
Losartan Potassium250$2,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$209$174,760189 claims
Novo NordiskOzempic, Wegovy$156$64,16254 claims
PfizerEliquis$60$45,09241 claims
GSKTrelegy Ellipta$95$21,28019 claims
Lilly USA, LLCMounjaro$121$20,53620 claims
AstraZenecaFarxiga$225$14,40312 claims
AbbVieLinzess$44$10,92611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Royal Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →